Scarica l'app Stockscreener
22.45
4.81%
1.03
Dopo l'orario di chiusura:
22.45
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché RARE Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$21.42
Aprire:
$21.05
Volume 24 ore:
1.77M
Relative Volume:
0.62
Capitalizzazione di mercato:
$2.21B
Reddito:
$672.72M
Utile/perdita netta:
$-575.44M
Rapporto P/E:
-3.8467
EPS:
-5.8361
Flusso di cassa netto:
$-487.00M
1 W Prestazione:
+12.25%
1M Prestazione:
-2.48%
6M Prestazione:
-27.35%
1 anno Prestazione:
-36.53%
Intervallo 1D:
$20.79
$22.45
Intervallo di 1 settimana:
$19.10
$22.45
Portata 52W:
$18.29
$42.37
Ultragenyx Pharmaceutical Inc Stock (RARE) Company Profile
Nome
Ultragenyx Pharmaceutical Inc
Settore
Industria
Telefono
415-483-8800
Indirizzo
60 LEVERONI COURT, NOVATO, CA
Compare RARE vs VRTX, REGN, ARGX, ALNY, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RARE
Ultragenyx Pharmaceutical Inc
|
22.45 | 2.21B | 672.72M | -575.44M | -487.00M | -5.8361 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Ultragenyx Pharmaceutical Inc Stock (RARE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-24 | Downgrade | Goldman | Buy → Neutral |
| 2025-10-20 | Iniziato | Wells Fargo | Overweight |
| 2025-07-28 | Ripresa | H.C. Wainwright | Buy |
| 2025-05-28 | Iniziato | William Blair | Outperform |
| 2024-06-06 | Aggiornamento | Goldman | Neutral → Buy |
| 2024-04-22 | Iniziato | RBC Capital Mkts | Outperform |
| 2023-12-08 | Iniziato | Wells Fargo | Overweight |
| 2023-06-14 | Ripresa | Credit Suisse | Outperform |
| 2023-06-06 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2023-04-26 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-01-18 | Ripresa | Canaccord Genuity | Buy |
| 2022-12-30 | Ripresa | H.C. Wainwright | Buy |
| 2022-11-03 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2022-10-13 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2022-08-01 | Downgrade | Evercore ISI | Outperform → In-line |
| 2022-03-16 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2022-02-11 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2021-09-30 | Iniziato | H.C. Wainwright | Buy |
| 2021-08-19 | Iniziato | UBS | Sell |
| 2021-07-15 | Iniziato | Guggenheim | Neutral |
| 2021-06-29 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2021-06-04 | Ripresa | Robert W. Baird | Neutral |
| 2021-05-06 | Aggiornamento | Citigroup | Neutral → Buy |
| 2021-05-06 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2021-04-26 | Ripresa | Credit Suisse | Neutral |
| 2021-03-02 | Ripresa | Stifel | Buy |
| 2021-02-12 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-12-07 | Downgrade | Wedbush | Outperform → Neutral |
| 2020-11-24 | Ripresa | Evercore ISI | In-line |
| 2020-11-12 | Downgrade | BofA Securities | Buy → Neutral |
| 2019-08-02 | Ripresa | Wedbush | Outperform |
| 2019-03-27 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2019-02-22 | Ripresa | Raymond James | Outperform |
| 2019-01-02 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2018-11-08 | Aggiornamento | Citigroup | Sell → Neutral |
| 2018-09-10 | Iniziato | Morgan Stanley | Equal-Weight |
| 2018-06-21 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2018-05-11 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2018-05-10 | Iniziato | Goldman | Neutral |
| 2018-04-18 | Aggiornamento | SunTrust | Hold → Buy |
| 2018-03-22 | Ripresa | Piper Jaffray | Overweight |
| 2018-02-21 | Reiterato | Stifel | Buy |
| 2018-01-22 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2018-01-18 | Iniziato | Credit Suisse | Outperform |
| 2017-12-05 | Reiterato | Barclays | Equal Weight |
| 2017-12-04 | Aggiornamento | Jefferies | Hold → Buy |
| 2017-09-14 | Aggiornamento | Wedbush | Neutral → Outperform |
Mostra tutto
Ultragenyx Pharmaceutical Inc Borsa (RARE) Ultime notizie
Bronstein, Gewirtz & Grossman LLC Urges Ultragenyx Pharmaceutical Inc. Investors to Act: Class Action Filed Alleging Investor Harm - Carroll County Mirror-Democrat
Ultragenyx Pharmaceutical Inc. (RARE) Class Action Lawsuit Seeks Recovery for Investors; April 6, 2026, DeadlineContact Kessler Topaz Meltzer & Check, LLP - Finansavisen
Aberdeen Group plc Buys 496,295 Shares of Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
Ultragenyx Pharmaceutical Hits 52-Week Low at $18.29 Amidst Declining Performance - Markets Mojo
RARE SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Reminds Ultragenyx Pharmaceutical (RARE) Investors of Securities Class Action Deadline on April 6, 2026 - PR Newswire
Ultragenyx says gene therapy accepted for FDA review again - MSN
Ultragenyx EVP Pinion sells $228k in shares - Investing.com
Ultragenyx Faces Lawsuit Deadline for Investor Losses - National Today
Ultragenyx 72 Hour Deadline Alert: Kahn Swick & Foti, LLC Reminds Investors With Losses In Excess Of $100,000 of Deadline in Class Action Lawsuit Against Ultragenyx Pharmaceutical Inc.RARE - The AI Journal
Rosen Law Firm Urges Ultragenyx Shareholders to File Claims - National Today
Mereo BioPharma Faces Deadline for Shareholder Vote - National Today
RARE Deadline: Rosen Law Firm Urges Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights - Business Wire
DEADLINE NEXT WEEK: Berger Montague Advises Ultragenyx Pharmaceutical Inc. (NASDAQ - MarketScreener
Ultragenyx Announces U.S. FDA Acceptance of BLA Resubmission for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA) - Bitget
ULTRAGENYX DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Ultragenyx Pharmaceutical Inc. Investors to Secure Counsel Before Important April 6 Deadline in Securities Class ActionRARE - accessnewswire.com
Insider Sell: Howard Horn Sells Shares of Ultragenyx Pharmaceuti - GuruFocus
Ultragenyx Pharmaceutical Inc. Class Action: Levi & Korsinsky Re - GuruFocus
FDA accepts Ultragenyx gene therapy application for rare disease By Investing.com - Investing.com Australia
Ultragenyx CFO Horn Howard sells $98k in shares By Investing.com - Investing.com India
Insider Selling: Ultragenyx Pharmaceutical (NASDAQ:RARE) CFO Sells 4,683 Shares of Stock - MarketBeat
Ultragenyx (RARE) CFO sells 4,683 shares, retains 80,351 stake - Stock Titan
ULTRAGENYX DEADLINE: ROSEN, RECOGNIZED INVESTOR COUNSEL, - GlobeNewswire
Morgan Stanley reiterates Ultragenyx stock rating on FDA filing progress By Investing.com - za.investing.com
Morgan Stanley reiterates Ultragenyx stock rating on FDA filing progress - Investing.com
Ultragenyx (RARE) Moves Forward with FDA Review of Gene Therapy Application - GuruFocus
Pomerantz LLP Notifies Investors of Class Action Lawsuit Against Ultragenyx Pharmaceutical Inc. – RARE - accessnewswire.com
Leerink reiterates Ultragenyx stock rating on gene therapy progress - Investing.com
RARE SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Reminds - GlobeNewswire
Ultragenyx Vaults Toward Commercialization as FDA Accepts Landmark Gene Therapy BLA - The Chronicle-Journal
Ultragenyx Shareholder Alert: ClaimsFiler Reminds Investors - GlobeNewswire
RARE Investors Have Opportunity to Lead Ultragenyx - GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Ultragenyx Pharmaceutical Inc. of Class Action Lawsuit and Upcoming DeadlinesRARE - PR Newswire
Ultragenyx BLA for UX111 Accepted for FDA Review - TipRanks
If regulatory approval is obtained, production of the gene therapy UX111 by Ultragenyx Pharmaceutical Inc (RARE) will take place in the United States, with plans to proceed simultaneously at both Andelyn Biosciences and Ultragenyx's own facilities. - Bitget
Ultragenyx resubmitted BLA for UX111 accepted with PDUFA date set for Sept. 19, 2026 - TradingView
FDA accepts Ultragenyx gene therapy application for rare disease - Investing.com
Ultragenyx (RARE) gets FDA review date for UX111 gene therapy on Sept. 19, 2026 - Stock Titan
FDA starts review of Ultragenyx gene therapy for fatal child disease - Stock Titan
Morgan Stanley Reaffirms “Buy” Rating on Ultragenyx Pharmaceutical (RARE) with $55 PT - MSN
Howard Horn sells multiple RARE shares (NASDAQ: RARE) under Form 144 - Stock Titan
Ultragenyx Pharmaceutical Inc. (RARE): A bull case theory - MSN
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) Q4 2025 earnings call transcript - MSN
Bronstein, Gewirtz & Grossman LLC Urges Ultragenyx Pharmaceutical Inc. Investors to Act: Class Action Filed Alleging Investor Harm - GlobeNewswire Inc.
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of April 6, 2026 in Ultragenyx LawsuitRARE - PR Newswire
Ultragenyx (RARE) Shares Positive Results From DTX301 Phase 3 Study - Insider Monkey
RARE Stock Price, Quote & Chart | ULTRAGENYX PHARMACEUTICAL IN (NASDAQ:RARE) - ChartMill
Ultragenyx Pharmaceutical Inc. Notice of April 6, 2026 Application Deadline for Class Action ... - Caledonian Record
Ultragenyx Pharmaceutical Inc. Notice of April 6, 2026 - GlobeNewswire
Ultragenyx Pharmaceutical Inc. Notice of April 6, 2026 Application Deadline for Class Action Lawsuit - GlobeNewswire Inc.
User - The Chronicle-Journal
Ultragenyx Pharmaceutical Reports FDA Acceptance of IND Application for UX016 - Bitget
Ultragenyx Pharmaceutical Inc Azioni (RARE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):